KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial.

Elizabeth Roof, Cheri L Deal, Shawn E McCandless, Ronald L Cowan, Jennifer L Miller, Jill K Hamilton, Elizabeth R Roeder, Shana E McCormack, Tamanna R Roshan Lal, Hussein D Abdul-Latif, Andrea M Haqq, Kathryn S Obrynba, Laura C Torchen, Alaina P Vidmar, David H Viskochil, Jean-Pierre Chanoine, Carol K L Lam, Melinda J Pierce, Laurel L Williams, Lynne M Bird, Merlin G Butler, Diane E Jensen, Susan E Myers, Oliver J Oatman, Charumathi Baskaran, Laura J Chalmers, Cary Fu, Nathalie Alos, Scott D McLean, Ajay Shah, Barbara Y Whitman, Brent A Blumenstein, Sarah F Leonard, Jessica P Ernest, Joseph W Cormier, Sara P Cotter, Davis C Ryman

J Clin Endocrinol Metab 108(7) 1696-1708

PMID36633570
PMCIDPMC10271225
DOI10.1210/clinem/dgad015
发表日期2023-01-12
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

CONTEXT: Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by endocrine and neuropsychiatric problems including hyperphagia, anxiousness, and distress. Intranasal carbetocin, an oxytocin analog, was investigated as a selective oxytocin replacement therapy. OBJECTIVE: To evaluate safety and efficacy of intranasal carbetocin in PWS. DESIGN: Randomized, double-blind, placebo-controlled phase 3 trial with long-term follow-up. SETTING: Twenty-four ambulatory clinics at academic medical centers. PARTICIPANTS: A total of 130 participants with PWS aged 7 to 18 years. INTERVENTIONS: Participants were randomized to 9.6 mg/dose carbetocin, 3.2 mg/dose carbetocin, or placebo 3 times daily during an 8-week placebo-controlled period (PCP). During a subsequent 56-week long-term follow-up period, placebo participants were randomly assigned to 9.6 mg or 3.2 mg carbetocin, with carbetocin participants continuing at their previous dose. MAIN OUTCOME MEASURES: Primary endpoints assessed change in hyperphagia (Hyperphagia Questionnaire for Clinical Trials [HQ-CT]) and obsessive-compulsive symptoms (Children's Yale-Brown Obsessive-Compulsive Scale [CY-BOCS]) during the PCP for 9.6 mg vs placebo, and the first secondary endpoints assessed these same outcomes for 3.2 mg vs placebo. Additional secondary endpoints included assessments of anxiousness and distress behaviors (PWS Anxiousness and Distress Behaviors Questionnaire [PADQ]) and clinical global impression of change (CGI-C). RESULTS: Because of onset of the COVID-19 pandemic, enrollment was stopped prematurely. The primary endpoints showed numeric improvements in both HQ-CT and CY-BOCS which were not statistically significant; however, the 3.2-mg arm showed nominally significant improvements in HQ-CT, PADQ, and CGI-C scores vs placebo. Improvements were sustained in the long-term follow-up period. The most common adverse event during the PCP was mild to moderate flushing. CONCLUSIONS: Carbetocin was well tolerated, and the 3.2-mg dose was associated with clinically meaningful improvements in hyperphagia and anxiousness and distress behaviors in participants with PWS. CLINICAL TRIALS REGISTRATION NUMBER: NCT03649477.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。